Raloxifene

Tissue-Selective ER Modulation#

Raloxifene is a benzothiophene SERM — it binds estrogen receptor α and β with high affinity but induces a receptor conformation distinct from estradiol or tamoxifen. That conformational difference is the whole game: it determines which co-activators and co-repressors get recruited in each tissue, which is why the same molecule acts as an antagonist in breast and uterus but a partial agonist in bone and liver.

"Raloxifene induces unique estrogen receptor conformations... acting as an antagonist in breast and uterine tissues, while acting as an agonist in bone and on lipid metabolism." — Muchmore DB, Oncologist, 2000

Practically, this is why raloxifene is the go-to for reversing established gyno: in mammary tissue it recruits co-repressors (NCoR, SMRT) and shuts down estrogen-driven ductal proliferation, while sparing the bone and lipid benefits of estrogenic signalling that matter when you're suppressed on cycle or cruising.

Antagonism in Breast Tissue — The Gyno Mechanism#

In glandular breast tissue, raloxifene blocks ERα-driven transcription of proliferative genes. The ligand (estradiol) is still circulating; raloxifene just occupies the receptor and prevents it from activating. This is a receptor-level block, not an estradiol-level block — which is the single most important thing to understand about running it.

That distinction is why raloxifene stacks with an AI rather than replacing it. The AI (aromasin, anastrozole) drops circulating E2; raloxifene covers the breast receptor. Both arms matter, especially on a tren or superdrol run where the nodule is already active. In the one head-to-head trial against tamoxifen in pubertal gyno, raloxifene cleared glandular tissue roughly twice as reliably:

"Fifty percent or greater reduction in glandular size occurred in 86% of those treated with raloxifene, compared with 41% of those treated with tamoxifen." — Lawrence SE et al., J Pediatr, 2004

Note the ceiling: raloxifene kills glandular tissue. Fibrotic, scarred, rubbery lumps older than a year don't respond to any SERM — that's a surgical problem.

Pituitary Antagonism and HPTA Effects#

At the hypothalamus/pituitary, raloxifene behaves as a mild ER antagonist — blocking estrogen's negative feedback on GnRH and pushing LH and FSH upward, with a corresponding rise in endogenous testosterone. The effect is real but weaker than tamoxifen or clomiphene, which is why raloxifene is not first-line for a pure HPTA restart. It earns its place in PCT when the user's primary concern is gyno rebound, or when tamoxifen produced intolerable sides (mood, vision, libido).

Unlike tamoxifen, raloxifene does not meaningfully suppress IGF-1 — a relevant detail for anyone running GH or trying to preserve the anabolic IGF-1 signal through PCT:

"No significant reduction in IGF-I levels was observed during therapy with raloxifene." — Torrisi R et al., Cancer Epidemiol Biomarkers Prev, 2001

Agonism in Bone and Lipid Metabolism#

In bone, raloxifene mimics estrogen — modulating RANKL/OPG signalling, suppressing osteoclast activity, and preserving BMD. In the liver, it exerts estrogen-like effects on lipid handling, lowering LDL without raising triglycerides the way oral estrogens do. For a male running long cruises with crushed endogenous estradiol, or anyone on an aggressive AI protocol, these agonist properties are a bonus rather than a downside — bone and lipid support come along for the ride.

Pharmacokinetics That Shape Dosing#

Raloxifene is absorbed efficiently but massively first-pass metabolised — conjugated to glucuronides in gut and liver before it ever reaches the systemic circulation:

"Raloxifene is rapidly absorbed after oral dosing, but systemic exposure to unchanged drug is low because of extensive first-pass conjugation to glucuronides in the intestine and liver." — Morello KC et al., Clin Pharmacokinet, 2003

Systemic bioavailability of unchanged drug is only ~2%, but the glucuronides undergo enterohepatic recycling — deconjugated back to active raloxifene in the gut and reabsorbed. This is what gives the compound its long ~27–32 hour half-life despite the brutal first pass, and why once-daily 60 mg dosing produces stable steady-state coverage. Metabolism is glucuronidation only — no CYP450 involvement — so raloxifene plays cleanly with AIs, finasteride, and essentially every other compound in a standard cycle support stack.

Class Risk: Thromboembolism#

The same estrogen-agonist activity that benefits bone and lipids also drives the one serious class effect of all SERMs — a pro-thrombotic signal through estrogenic effects on hepatic clotting factor synthesis:

"There was an increased risk of venous thromboembolic events in women assigned to raloxifene, consistent with other SERMs." — Cummings SR et al., JAMA, 1999

Roughly 2–3× baseline DVT/PE risk. Hard contraindication in anyone with personal or strong family history of VTE, known thrombophilia (Factor V Leiden, prothrombin mutation, antiphospholipid syndrome), or prolonged immobilization. Smokers stacking AAS and raloxifene are compounding clot risk — treat this risk seriously; discontinuation is recommended before long flights or surgery, and unilateral calf pain should prompt a DVT workup rather than being dismissed as a cramp.

Common (most users)#

• Calf and leg cramps — the signature raloxifene side effect in male users. Magnesium glycinate 400mg at night, adequate hydration, and splitting the dose (30mg AM + 30mg PM, or 60mg AM + 60mg PM at the higher tier) knocks most of this out. If cramps persist at 120mg/day, reducing to 60mg and extending the run is reasonable.
• Mild hot flashes / flushing — transient, typically resolves in 2–4 weeks as the body adjusts to ER antagonism. No intervention needed.
• Minor joint or muscle aches — usually mild, mimics low-estrogen AI territory. If you're running an AI concurrently and aches are severe, your estradiol is crashed — that's the AI, not the raloxifene. Pull bloods.
• Slight libido dip / softer erections in a minority of users — usually dose-dependent, resolves on discontinuation. Tadalafil 5mg daily handles it cleanly if you want to keep the raloxifene run intact.
• Headaches — usually resolve within the first 1–2 weeks; hydration and caffeine moderation help.

Uncommon (dose-dependent or individual)#

• Elevated liver enzymes — uncommon, but worth checking. Pull ALT/AST at baseline and again at 6–8 weeks, especially if stacking with oral AAS. If ALT creeps above 3× upper limit, drop the orals first before blaming the raloxifene.
• Peripheral edema — mild ankle/lower-leg swelling at 120mg/day in some users. Back off to 60mg if it's cosmetic; investigate if it's unilateral (see clot warning below).
• Persistent flushing / sweats past the 4-week mark — uncommon; consider splitting the dose or swapping to tamoxifen if the user tolerates it better.
• Breast tenderness paradox — rarely, users report a short flare of nipple sensitivity in the first 1–2 weeks as receptor dynamics shift. If it's not improving by week 3, reassess — you may be dealing with a prolactin-driven lesion that needs cabergoline, not a SERM.
• GI upset — mild nausea, occasional loose stools. Take with food; rarely dose-limiting.

Rare but serious#

• Venous thromboembolism (DVT / PE) — the one side effect that actually matters. The MORE trial documented a clear class-effect increase in clot risk on raloxifene:

"There was an increased risk of venous thromboembolic events in women assigned to raloxifene, consistent with other SERMs." — Cummings et al. 1999, JAMA

Warning signs: unilateral calf swelling, warmth, or a dull ache that isn't symmetric cramping; sudden shortness of breath; pleuritic chest pain; unexplained tachycardia. That is an ER visit and a D-dimer, not a "push through it" moment. Stop raloxifene immediately and get imaged.

• Stroke / TIA — low absolute incidence but a recognized SERM-class signal, particularly in users with additional cardiovascular risk factors. Sudden unilateral weakness, vision loss, or aphasia → emergency.
• Hepatotoxicity — rare, but discontinue immediately if jaundice, dark urine, or RUQ pain develops.
• Severe hypertriglyceridemia — rare in men; more of an issue in users with pre-existing lipid disorders. Annual lipid panel covers this.

Hard contraindications#

• Pregnancy or possibility of pregnancy — Category X. Teratogenic. Anyone who could become pregnant uses reliable contraception or does not run this compound.
• Personal or strong family history of DVT, PE, or stroke — do not run raloxifene. Full stop.
• Known thrombophilia (Factor V Leiden, prothrombin G20210A, antiphospholipid syndrome, protein C/S deficiency) — do not run.
• Prolonged immobilization — surgery, long-haul flights, post-injury bed rest. Discontinue raloxifene at least 72 hours before and throughout the immobilization period.
• Active hepatic impairment — raloxifene is not metabolized by CYP450 but is extensively glucuronidated in the liver; impaired conjugation means unpredictable exposure.
• Untreated, uncontrolled hypertension on a heavy AAS cycle — the combined cardiovascular and thrombotic load is not worth it. Get BP managed first.
• Smokers running AAS — you are already stacking clot risk. If you won't quit, at minimum understand you're amplifying the MORE-trial signal in a population that wasn't even in the trial.

Gender, fertility, and PCT considerations#

Male use of raloxifene is entirely off-label; long-term safety data in men beyond small trials is thin, though two decades of community use at 60–120mg/day has not surfaced signals beyond the expected SERM-class clot risk. Unlike tamoxifen, raloxifene does not meaningfully suppress IGF-1 — a real advantage for users wanting to preserve the anabolic signal through a gyno rescue or PCT:

"No significant reduction in IGF-I levels was observed during therapy with raloxifene." — Torrisi et al. 2001, Cancer Epidemiology, Biomarkers & Prevention

For PCT, raloxifene is a weaker HPTA restart agent than tamoxifen or clomiphene — use it as the SERM arm of PCT specifically when gyno rebound is the priority risk, or when tamoxifen produced intolerable sides (mood, vision, IGF-1 suppression). For straight HPTA restart without gyno concerns, tamoxifen + clomiphene remains the stronger pair. Premenopausal women do not use this compound for PED-adjacent purposes — the pregnancy contraindication is absolute and the approved indications (postmenopausal osteoporosis, breast cancer risk reduction) don't translate.